Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06081426

Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

Location status: Recruiting

Location contact

Jill Morris-Tillman

CONTACT

[email protected]

412-383-8206

Mary L Phillps, MD, MD

PRINCIPAL_INVESTIGATOR

About this study

The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All participants:

  • 18-40 years of age
  • Not following a ketogenic diet

BD hypomanic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% Bipolar I: Bipolar II (BDI:II) (Diagnostic and Statistical Manual of Mental Disorders 5; DSM-5)
  • Score greater than 10 on the Young Mania Rating Scale score(YMRS)
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)

BD euthymic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% BDI:II (DSM-5)
  • Score less than or equal to 10 on YMRS
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)

Healthy Control (HC) Group (n=30):

  • Sex matched with BD groups
  • No psychiatric history

Exclusion criteria

All participants:

  • Not between 18-40 years of age
  • History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
  • Mini-Mental State Examination score (cognitive state) <24
  • Premorbid National Adult Reading Test Intelligent Quotient (NAART IQ) estimate<85
  • Visual disturbance: <20/40 Snellen visual acuity
  • History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
  • MRI exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
  • Unable to understand English
  • Conditions related to the pancreas, liver, thyroid or gallbladder.
  • Taking anticoagulants and/or those with blood dyscrasias (illnesses) who have coagulation disorders (eg, hemophilia) because of the ketomojo finger stick blood tests
  • Scoring 3 or higher on positive symptom factor questions on the Positive and Negative Syndrome Scale (PANSS) questionnaire (indicative of psychotic symptoms)
  • Currently following a ketogenic diet
  • Head circumference larger than 24 inches (62cm) and/or chest circumference larger than 55 inches (139 cm)

BD hypomanic group:

  • Must be meeting sex proportions: not 50% female
  • Must be meeting diagnosis proportions: not 50:50% BDI:II (DSM-5)
  • Diagnosis of BD in a manic or euthymic episode
  • Score 10 or lower on the Young Mania Rating Scale score(YMRS)
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app

BD euthymic group:

  • Not meeting sex proportion: not 50% female
  • Not meeting diagnosis proportion: not 50:50% BDI:II
  • Diagnosis of BD in a depressive, hypomanic, or manic episode
  • Score greater than 10 on YMRS
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app

Healthy Control (HC) Group

  • Not sex-matched with BD groups
  • Has psychiatric history

Treatment and study plan

Non-ketogenic Diet

Other

Consuming a non-ketogenic diet

Ketogenic diet

Other

Consuming a ketogenic diet

No diet

Other

Participants without Bipolar Disorder will not participate in the diet phases of the study

Primary outcomes

  1. Blood oxygen level-dependent (BOLD) signal at Scan 1

    Time frame: Baseline Scan 1 (all participants)

    The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

  2. Blood oxygen level-dependent (BOLD) signal at Scan 2

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

  3. Blood oxygen level-dependent (BOLD) signal at Scan 3

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

  4. Manic symptoms at Scan 1

    Time frame: Baseline Scan 1 (all participants)

    The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

  5. Manic symptoms at Scan 2

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

  6. Manic symptoms at Scan 3

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

  7. Fasting Glucose at Baseline

    Time frame: Baseline (all participants)

    Fasting glucose blood levels

  8. Fasting lipids at Baseline

    Time frame: Baseline (all participants)

    Fasting lipid blood levels

  9. Fasting hepatic function panel at Baseline: total protein

    Time frame: Baseline (all participants)

    Fasting levels of total protein in the blood

  10. Fasting hepatic function panel at Baseline: albumin

    Time frame: Baseline (all participants)

    Fasting levels of albumin in the blood

  11. Fasting hepatic function panel at Baseline: bilirubin

    Time frame: Baseline (all participants)

    Fasting levels of bilirubin in the blood

  12. Fasting hepatic function panel at Baseline: liver enzyme

    Time frame: Baseline (all participants)

    Fasting levels of liver enzyme in the blood

  13. Fasting Glucose at halfway point through first dietary phase

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting glucose blood levels

  14. Fasting lipids at halfway point through first dietary phase

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting lipid blood levels

  15. Fasting hepatic function at halfway point through first dietary phase: total protein

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of total protein in the blood

  16. Fasting hepatic function at halfway point through first dietary phase: albumin

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of albumin in the blood

  17. Fasting hepatic function at halfway point through first dietary phase: bilirubin

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of bilirubin in the blood

  18. Fasting hepatic function at halfway point through first dietary phase: liver enzyme

    Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of liver enzyme in the blood

  19. Fasting Glucose at end of first dietary phase

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting glucose blood levels

  20. Fasting lipids at end of first dietary phase

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting lipid blood levels

  21. Fasting hepatic function at end of first dietary phase: total protein

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of total protein in the blood

  22. Fasting hepatic function at end of first dietary phase: albumin

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of albumin in the blood

  23. Fasting hepatic function at end of first dietary phase: bilirubin

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of bilirubin in the blood

  24. Fasting hepatic function at end of first dietary phase: liver enzyme

    Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of liver enzyme in the blood

  25. Fasting Glucose at halfway point through second dietary phase

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting glucose blood levels

  26. Fasting lipids at halfway point through second dietary phase

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting lipid blood levels

  27. Fasting hepatic function at halfway point through second dietary phase: total protein

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of total protein in the blood

  28. Fasting hepatic function at halfway point through second dietary phase: albumin

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of albumin in the blood

  29. Fasting hepatic function at halfway point through second dietary phase: bilirubin

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of bilirubin in the blood

  30. Fasting hepatic function at halfway point through second dietary phase: liver enzyme

    Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

    Fasting levels of liver enzyme in the blood

  31. Fasting Glucose at end of second dietary phase

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting glucose blood levels

  32. Fasting lipids at end of second dietary phase

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting lipids blood levels

  33. Fasting hepatic function at end of second dietary phase: total protein

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of total protein in the blood

  34. Fasting hepatic function at end of second dietary phase: albumin

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of albumin in the blood

  35. Fasting hepatic function at end of second dietary phase: bilirubin

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of bilirubin in the blood

  36. Fasting hepatic function at end of second dietary phase: liver enzyme

    Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Fasting levels of liver enzyme in the blood

  37. Gamma-aminobutyric acid (GABA) at Baseline

    Time frame: Baseline Scan 1 (all participants)

    Gamma-aminobutyric acid (GABA) concentrations in the brain

  38. Glutamate at Baseline

    Time frame: Baseline Scan 1 (all participants)

    Glutamate concentrations in the brain

  39. Lactate at Baseline

    Time frame: Baseline Scan 1 (all participants)

    Lactate concentrations in the brain

  40. Gamma-aminobutyric acid (GABA) at end of first dietary phase

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Gamma-aminobutyric acid (GABA) concentrations in the brain

  41. Glutamate at end of first dietary phase

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Glutamate concentrations in the brain

  42. Lactate at end of first dietary phase

    Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Lactate concentrations in the brain

  43. Gamma-aminobutyric acid (GABA) at end of second dietary phase

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Gamma-aminobutyric acid (GABA) concentrations in the brain

  44. Glutamate at end of second dietary phase

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Glutamate concentrations in the brain

  45. Lactate at end of second dietary phase

    Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Lactate concentrations in the brain

Secondary outcomes

  1. Average total sleep time during Ketogenic vs Normal diet

    Time frame: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals

    Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home.

  2. Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet

    Time frame: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.

    Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home

  3. Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring

    Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

  4. Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring

    Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

  5. Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring

    Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

  6. Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring

    Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

  7. Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring

    Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

  8. Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring

    Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

    Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

Study contacts

Contact information is provided by the study sponsor or research team.

Jill Morris-Tillman

CONTACT

[email protected]

412-383-8206

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Collaborators

  • Baszucki Brain Research Fund

Registry information

Official study title

Elucidating Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD): a Multidisciplinary Mechanistic Study

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 13, 2023
Registry last updated
Dec 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.